| __timestamp | Lantheus Holdings, Inc. | Xencor, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 13673000 | 18516000 |
| Thursday, January 1, 2015 | 14358000 | 34140000 |
| Friday, January 1, 2016 | 12203000 | 51872000 |
| Sunday, January 1, 2017 | 18125000 | 71772000 |
| Monday, January 1, 2018 | 17071000 | 97501000 |
| Tuesday, January 1, 2019 | 20018000 | 118590000 |
| Wednesday, January 1, 2020 | 32788000 | 169802000 |
| Friday, January 1, 2021 | 44966000 | 192507000 |
| Saturday, January 1, 2022 | 311681000 | 199563000 |
| Sunday, January 1, 2023 | 77707000 | 253598000 |
Unleashing insights
In the ever-evolving landscape of biotechnology, research and development (R&D) investments are pivotal. Over the past decade, Lantheus Holdings, Inc. and Xencor, Inc. have demonstrated contrasting strategies in their R&D expenditures. From 2014 to 2023, Xencor, Inc. consistently outpaced Lantheus Holdings, Inc., with a peak investment in 2023 that was approximately 3.3 times higher than Lantheus's. Notably, Lantheus saw a dramatic surge in 2022, with R&D spending skyrocketing by over 600% compared to the previous year, highlighting a strategic pivot. Meanwhile, Xencor's steady increase reflects a commitment to sustained innovation, culminating in a 37% rise from 2022 to 2023. These trends underscore the dynamic nature of R&D investment strategies in the biotech sector, where companies must balance immediate financial constraints with long-term innovation goals.
Research and Development Expenses Breakdown: Gilead Sciences, Inc. vs Lantheus Holdings, Inc.
Comparing Innovation Spending: Regeneron Pharmaceuticals, Inc. and Xencor, Inc.
Research and Development: Comparing Key Metrics for Alnylam Pharmaceuticals, Inc. and Lantheus Holdings, Inc.
Analyzing R&D Budgets: Halozyme Therapeutics, Inc. vs Lantheus Holdings, Inc.
Lantheus Holdings, Inc. or Corcept Therapeutics Incorporated: Who Invests More in Innovation?
Who Prioritizes Innovation? R&D Spending Compared for Lantheus Holdings, Inc. and PTC Therapeutics, Inc.
Research and Development: Comparing Key Metrics for Lantheus Holdings, Inc. and Catalyst Pharmaceuticals, Inc.
R&D Spending Showdown: Lantheus Holdings, Inc. vs MiMedx Group, Inc.
Research and Development Expenses Breakdown: Ionis Pharmaceuticals, Inc. vs Xencor, Inc.
Comparing Innovation Spending: Amneal Pharmaceuticals, Inc. and Xencor, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Apellis Pharmaceuticals, Inc. and Xencor, Inc.
Ligand Pharmaceuticals Incorporated vs Xencor, Inc.: Strategic Focus on R&D Spending